GTB-3650
Phase 1- Indications
- Acute myeloid leukemia, Myelodysplastic syndrome
Company intelligence / Profile preview
GT Biologics
Aberdeen, Scotland, United Kingdomgtbiopharma.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
GT Biologics is a UK-based company founded in 2008 that develops medicines leveraging potent immune-regulating properties for novel therapies. Specific clinical results are not publicly available.
- Therapeutic areas
- Immunology
- Modalities
- Microbial therapyLive biotherapeutic product therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on GT Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GT Biologics.